Cannabidiol / NRF2 Cancer Research Results

CBD, Cannabidiol: Click to Expand ⟱
Features:
Cannabidiol (CBD) is a cannabinoid compound found in cannabis plants.
Cannabidiol (CBD) is a non-psychoactive phytocannabinoid derived from Cannabis sativa that has drawn interest for its potential anticancer properties.
Pathways:
-Mitochondrial dysfunction, with loss of membrane potential leading to the release of cytochrome c and activation of caspase cascades
-Receptor-Mediated Signaling (CB Receptors and Beyond)
-Can increase reactive oxygen species (ROS)
-Can induce ER stress, which activates the unfolded protein response.
-Suppress key survival and proliferation signaling cascades such as the PI3K/Akt/mTOR pathway.
-Impair angiogenesis

Cannabidiol — Cannabidiol (CBD) is a non-intoxicating phytocannabinoid from Cannabis sativa with pleiotropic signaling effects that include ion-channel modulation, lipid-membrane stress, mitochondrial injury, oxidative stress induction, and context-dependent receptor/transcriptional effects. It is formally classified as a plant-derived cannabinoid small molecule and, clinically, as the active ingredient of the FDA-approved oral drug Epidiolex for certain seizure disorders rather than for cancer treatment. Standard abbreviations include CBD; the major acidic biosynthetic precursor is CBDA. For oncology, the evidence base is still mainly preclinical, with recurrent themes of apoptosis or autophagic death, EMT and invasion suppression, and chemo-sensitization in selected models, but translation is constrained by formulation-dependent exposure, extensive first-pass metabolism, and clinically important drug-interaction and hepatic-safety considerations.

Primary mechanisms (ranked):

  1. Mitochondrial stress with ROS increase, membrane depolarization, and intrinsic cell-death signaling.
  2. TRP-channel mediated Ca²⁺ dysregulation, especially TRPV2 or TRPV4-linked stress responses in glioma models.
  3. ER stress and integrated stress-response signaling, including ATF4–DDIT3/CHOP-associated death programs.
  4. PI3K/Akt/mTOR survival-axis suppression with secondary effects on proliferation, autophagy, and metabolic fitness.
  5. Anti-migratory and anti-metastatic signaling, including EMT reversal and Wnt/β-catenin suppression in colorectal cancer models.
  6. PPARγ-associated pro-death and anti-proliferative signaling in some tumor contexts.
  7. Ceramide-linked stress signaling in pancreatic cancer models.
  8. Chemosensitization through enhanced drug uptake or stress amplification in selected models, especially glioma.

Bioavailability / PK relevance: CBD is highly lipophilic, has low and formulation-sensitive oral bioavailability, and undergoes extensive hepatic and gut metabolism primarily via CYP2C19, CYP3A4, and UGT pathways. Food markedly changes exposure; high-fat meals can increase systemic exposure several-fold. The approved prescription formulation has a long terminal half-life after repeated dosing, but oncology studies and commercial products are heterogeneous in formulation, route, and reliability of exposure.

In-vitro vs systemic exposure relevance: This is a major translation constraint. Many anticancer in-vitro studies use low-to-moderate or higher micromolar concentrations that may not be reproducibly achievable in tumors with standard oral dosing, especially with non-pharmaceutical products. Some local-delivery, inhaled, or nanoformulation approaches may improve relevance, but for most cancer contexts the mechanistic literature still outpaces clinically validated exposure-response data.

Clinical evidence status: Preclinical evidence is substantial. Human cancer evidence is limited to small early-phase studies, supportive-care trials, and ongoing exploratory cancer trials; there is no established cancer-directed indication. Current oncology guidance supports discussing cannabis or cannabinoids for selected supportive-care scenarios but recommends against using them as anticancer therapy outside clinical trials.

-Liver injury is one of the main labeled toxicities: ALT elevations above 3× ULN occurred in 12% to 13% of treated patients in controlled studies

Mechanistic ranking

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial ROS and membrane injury ROS ↑; ΔΨm ↓; cytochrome c release ↑; caspase signaling ↑ ↔ or less sensitive in some models R/G Apoptosis or lethal stress Most central cross-tumor mechanism; often upstream of apoptosis and stress-pathway collapse.
2 TRPV2 or TRPV4 Ca²⁺ influx Ca²⁺ influx ↑; stress signaling ↑; drug uptake ↑ Limited effect reported in some astrocyte comparisons P/R Autophagy, apoptosis, chemosensitization Especially relevant in glioma literature; supports both direct cytotoxicity and adjunct sensitization.
3 ER stress and integrated stress response ATF4 ↑; DDIT3 CHOP ↑; UPR stress ↑ Usually weaker or not well defined R/G Death-program engagement Frequently coupled to Ca²⁺ dysregulation, ceramide changes, and mitochondrial dysfunction.
4 PI3K Akt mTOR survival signaling PI3K/Akt/mTOR ↓ ↔ (context-dependent) R/G Reduced survival and growth A common convergence node rather than always the initiating lesion.
5 Apoptosis execution program Apoptosis ↑; caspase 3 8 9 ↑; PARP cleavage ↑ ↔ or less pronounced in selected comparisons G Tumor cell loss Robust downstream phenotype across many cell systems.
6 Autophagy and mitophagy Autophagy ↑; mitophagy arrest or lethal autophagy ↑ Unclear selectivity R/G Stress adaptation failure or non-apoptotic death Can be cytotoxic or partially adaptive depending on model; important in glioma work.
7 EMT and Wnt β-catenin axis Wnt/β-catenin ↓; Snail ↓; vimentin ↓; E-cadherin ↑; metastasis programs ↓ Not established as a core normal-cell effect G Migration and invasion suppression Strong recent relevance in colorectal cancer models
8 PPARγ signaling PPARγ ↑ ↔ (context-dependent) R/G Pro-apoptotic transcriptional shift Mechanistically meaningful but not universal across tumor types.
9 Mitochondrial ROS increase secondary redox axis ROS ↑ Potential antioxidant or mixed effects in non-cancer settings P/R Stress amplification Include as a secondary redox axis rather than as the sole mechanism because CBD redox effects are context-dependent.
10 HIF-1α and angiogenesis signaling HIF-1α ↓; pro-angiogenic tone ↓ Not clearly established clinically G Vascular support restraint Present in preclinical literature, but not a top translation driver.
11 Ceramide stress signaling CerS1 ↑; ceramide stress ↑ Unknown R/G ER stress linked cytotoxicity Currently most notable in pancreatic cancer work; may be subtype-specific.
12 Glycolysis and lipogenesis Lipogenesis ↓; metabolic fitness ↓ Systemic lipid effects also occur outside oncology G Metabolic disadvantage Mechanistically relevant but less mature as a core anticancer axis than stress-death signaling.
13 Chemosensitization Sensitivity to cytotoxics ↑ Potential therapeutic window depends on regimen G Adjunct leverage Most persuasive in glioma and some combination-model systems; clinically still exploratory.
14 Clinical Translation Constraint Micromolar in-vitro activity often exceeds routine systemic tumor exposure Normal-tissue PK and DDI burden remain clinically relevant G Limits standalone translation Poor and meal-sensitive oral bioavailability, product heterogeneity, hepatic injury risk, sedation, and CYP UGT interactions are major constraints.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
6510- BCP,  CBD,    Cannabidiol and Beta-Caryophyllene Combination Attenuates Diabetic Neuropathy by Inhibiting NLRP3 Inflammasome/NFκB through the AMPK/sirT3/Nrf2 Axis
- in-vivo, Nor, NA
*MMP↓, *ROS↑, *BloodF↑, *Pain↓, *antiOx↑, *Inflam↓, *AMPK↑, *SIRT3↑, *NRF2↑, *PINK1↑, *PARK2↑, *LC3B↑, *Beclin-1↑, *TFAM↑, *NLRP3↓, *NF-kB↓, *COX2↓, *p62↓, *NP/CIPN↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

TFAM↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 1,   NRF2↑, 1,   PARK2↑, 1,   ROS↑, 1,   SIRT3↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   PINK1↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3B↑, 1,   p62↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   Inflam↓, 1,   NF-kB↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Clinical Biomarkers ⓘ

BloodF↑, 1,  

Functional Outcomes ⓘ

NP/CIPN↓, 1,   Pain↓, 1,  
Total Targets: 19

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:54  Target#:226  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page